+ Watch PPHM
on My Watchlist
A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.
The other day I saw one of the nurses with a new hairstyle. I thought I'd be funny so I told her she looked different that day? "Didn't you use to have a mustache?" I asked her. She gave me a weird look and scurried away. Later I found out she'd had her upper lip waxed too.Now that's embarrassing. But not half as embarrassing as red thumbing Peregrine one day before they came out with positive PR on their withdrawn OS data from the phase II bavituximab lung cancer trial. In retrospect, I realized I was so eager to regain score leadership on Peregrine that I was ignoring the substantial likelihood of a PR like this one. A stock like this is just too juicy for mono traders to stay in the pennies.I'm still confident that bavituximab is inert, for the same reasons I had before the bogus OS data was released in the first place. But Peregrine won't die easily and now I may have to wait months before getting another chance to play.
Did she happen to smell like Honey Nut Cheerios?
On a brighter note... at least you learned what pick up line not to use next time. ;)
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions